"A 2010 study published in the Lancet suggested what medicine, recently found to reduce cancer development, aside from giving protection against strokes and heart attacks, is ""...the most amazing drug in the world...""?"
Garret A. FitzGerald and Drug Administration (FDA). FitzGerald's work contributed substantially to the development of low-dose aspirin to prevent heart attacks and strokes. FitzGerald's lab was the first to predict and then mechanistically explain the cardiovascular hazard from Nonsteroidal anti-inflammatory drugs (NSAIDs), a common class of painkiller. His work showing that selective COX-2 inhibitors depress the production of prostacyclin in the endothelium, thereby increasing cardiovascular risk, was instrumental in the withdrawal of Vioxx (rofecoxib) from the U.S. market in 2004. FitzGerald is a member of the National Academy of Medicine, the American Academy of Arts and Sciences, the Royal Society, the Accademia dei
The Lancet in October 2005. Several articles in other scientific journals were withdrawn following the withdrawal in "The Lancet". Within a week, the "New England Journal of Medicine" published an expression of editorial concern regarding its published research papers by the same author, and in November 2006 the journal withdrew two oral cancer studies led by the Norwegian researcher. In August 2010, "The Lancet Infectious Diseases" published an article about an enzyme conferring multi-drug-resistance properties in bacteria, which had previously been named New Delhi metallo-beta-lactamase or NDM-1 based on the assumed origin of the mechanism. The article reported 44 clinical isolates of